Xcout Intel
BioArctic AB
BioArctic AB (publ) is an innovative Swedish research-based biopharma company headquartered in Stockholm, Sweden. Incorporated in 2000, it focuses on developing disease-modifying treatments for neurodegenerative diseases. The company is publicly traded and committed to corporate governance.
Subscribe to see BioArctic AB’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
BioArctic AB at a glance
BioArctic AB is a biotech company headquartered in Sweden. Xcout tracks 2 named people at BioArctic AB, including Lars Lannfelt (Professor).
BioArctic AB leadership
- Lars LannfeltProfessor
- Pär GellerforsCo-founder
BioArctic AB competitors
A few of BioArctic AB's closest competitors — see the full list of competitors and alternatives →
BioArctic AB is a Swedish biopharmaceutical company developing disease-modifying treatments for neurodegenerative disorders, particularly Alzheimer’s and Parkinson’s disease. It serves patients and healthcare systems through its own drug-development programs and partnerships with pharmaceutical companies, including Eisai.
Alzinova AB is a Swedish clinical-stage biopharmaceutical company that develops disease-modifying treatments and vaccines targeting Alzheimer's disease. Utilizing its proprietary AβCC Peptide technology, the company focuses on creating therapeutics for Alzheimer's patients to address high unmet medical needs in neurodegeneration.
Muna Therapeutics is a privately held biopharmaceutical company founded in 2020 with headquarters in Copenhagen, Denmark, and operations in Leuven. The company discovers and develops novel therapies aimed at slowing or stopping devastating neurodegenerative diseases like Alzheimer's and Parkinson's.
Umecrine Cognition AB is a Swedish clinical-stage pharmaceutical company based at the Karolinska Institutet Science Park in Solna, developing a novel class of drugs to treat neurological disorders of the brain.
Alzheon, Inc. is a clinical-stage biopharmaceutical company headquartered in Framingham, Massachusetts. Founded in 2013, the company is dedicated to developing a broad portfolio of investigational therapeutic products for neurodegenerative disorders, including Alzheimer's disease. Its research centers on advancing disease-modifying treatments for patients with cognitive decline.
AriBio is a clinical-stage biopharmaceutical company founded in 2010 and headquartered in Seongnam, South Korea, with additional offices in the United States. The company focuses on developing novel therapeutics for neurodegenerative diseases.
Get BioArctic AB's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on BioArctic AB in Xcout Intel
- 2 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access